TNXP is presently in a Ph3 study of their lead treatment for military PTSD-related symptoms (nightmares and insomnia)
Tonmya is a sublingual intended to block an adrenergic receptor associated with nightmares. In Ph2, it showed a dose response relationship but did not meet the primary endpoint.
A significant side-effect of Tonmya is severe oral numbness
The active ingredient for Tonmya is also available in a generic pill.
Tonmya is also entering a Ph2 study for agitation in Alzheimer disease, where there are no competing treatments. The problem here is that the tongue/oral numbness side effect may derail its commercial viability.
With the company's recently announced $75mn-secondary, TNXP has a cash runway into the middle of 2020.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.